pegylated CD25/CD122-selective interleukin-2 mutein STK-012

{
  "id": "MLC-T-ONC-015920",
  "term": "pegylated CD25/CD122-selective interleukin-2 mutein STK-012",
  "field": "Oncology and biomedicine",
  "definition": "A pegylated, engineered variant form of the human cytokine interleukin 2 (IL-2; IL2), with selective binding affinity for IL-2 receptor subunit alpha (IL-2Ralpha; CD25) and beta (IL-2Rbeta; CD122), with potential immunoregulatory and antineoplastic activities. Upon administration, pegylated CD25/CD122-selective IL-2 mutein STK-012 targets and binds to CD25 and CD122 on antigen-activated effector T cells and activates CD25/CD122-mediated signaling. This activates cytotoxic T lymphocytes (CTLs), enhances T-cell-mediated tumor cell killing and decreases tumor cell proliferation. STK-012 does not activate peripheral natural killer (NK) and naive T cells, thereby circumventing the exacerbation of vascular leak syndrome (VLS) and other NK cell-mediated adverse effects associated with recombinant IL-2. CD25 and CD122 are highly expressed in antigen-activated and tumor-specific T cells.",
  "synonyms": [
    "IL-2 partial agonist STK-012",
    "interleukin-2 partial agonist STK-012",
    "pegylated CD25/CD122-selective IL-2 mutein STK-012",
    "pegylated alpha/beta-selective IL-2 mutein STK-012",
    "pegylated alpha/beta-biased engineered interleukin-2 STK-012"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pegylated-cd25-cd122-selective-interleukin-2-mutein-stk-012/"
}